IN CASE YOU MISSED IT: The Richmond Times Dispatch published the below op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse. In this must-read piece, Lane praises the bipartisan efforts of Representatives Abigail Spanberger (D-VA) and Tom Reed (R-NY) to rein in Big Pharma’s patent abuse. Their bill, the Biologic Patent Transparency Act, would bring much-needed transparency […]

Continue Reading

Urges Representatives to Take Further Measures Toward Ending Big Pharma’s Patent Abuse WASHINGTON, D.C. – The Coalition Against Patent Abuse, a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others released the following statement commending the House Judiciary Committee for voting, on a bipartisan basis, to advance theAffordable Prescriptions for […]

Continue Reading

IN CASE YOU MISSED IT: This evening, The Wall Street Journal published a must-read report highlighting the harmful impact Big Pharma’s patent abuse is having on the ability of American patients to access more affordable generic drug alternatives.  According to this eye-opening report, despite a record number of generic drugs for cancer and other serious ailments, major drug companies […]

Continue Reading

WHAT YOU NEED TO KNOW On Thursday, Patients for Affordable Drugs (P4AD) released a report “The Truth About Insulin Prices” as part of a campaign for World Diabetes Day. The report shows how pharmaceutical companies have kept the prices of insulin artificially high by manipulating the patent system. The report notes that, “… insulin manufacturers have […]

Continue Reading

Humira Revenue Up 9.6% In U.S., But Down Abroad Due To Biosimilar IN CASE YOU MISSED IT: The poster child for how big, brand-name drug companies abuse the patent system to keep drug prices high continues to reap the benefits from gaming the U.S. patent system. Yesterday, Inside Health Policy reported that Abbvie’s revenue from Humira […]

Continue Reading

WHAT YOU NEED TO KNOW This Wednesday, the Senate Judiciary Subcommittee on Intellectual Property held a hearing on the need to strengthen patent quality and prevent the spread of low-quality and invalid patents, which have contributed in part to high drug prices. CAPA released a statement commending Sen. Tillis (R-NC) for holding this hearing and […]

Continue Reading